Holen Sie sich die Stockscreener-App
3.01
16.62%
-0.60
Handel nachbörslich:
3.03
0.02
+0.66%
Schlusskurs vom Vortag:
$3.61
Offen:
$3.56
24-Stunden-Volumen:
11.63M
Relative Volume:
3.34
Marktkapitalisierung:
$275.31M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-67.68M
KGV:
-1.8133
EPS:
-1.66
Netto-Cashflow:
$-54.24M
1W Leistung:
+7.89%
1M Leistung:
+23.36%
6M Leistung:
+124.63%
1J Leistung:
-18.87%
1-Tages-Spanne:
$2.75
$3.575
1-Wochen-Bereich:
$2.39
$3.67
52-Wochen-Spanne:
$0.9857
$5.46
Cabaletta Bio Inc Stock (CABA) Company Profile
Firmenname
Cabaletta Bio Inc
Sektor
Branche
Telefon
(267) 759-3100
Adresse
2929 ARCH STREET, PHILADELPHIA, PA
Vergleichen Sie CABA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
3.01 | 330.19M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Fortgesetzt | Jefferies | Buy |
| 2024-12-20 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | Eingeleitet | UBS | Buy |
| 2024-02-05 | Eingeleitet | Jefferies | Buy |
| 2023-11-29 | Eingeleitet | William Blair | Outperform |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Eingeleitet | Stifel | Buy |
| 2023-09-05 | Eingeleitet | Citigroup | Buy |
| 2023-07-18 | Eingeleitet | Guggenheim | Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-06-30 | Eingeleitet | Mizuho | Buy |
| 2021-01-08 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-19 | Eingeleitet | Cowen | Outperform |
| 2019-11-19 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-19 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Cabaletta Bio Inc Aktie (CABA) Neueste Nachrichten
Tools to assess Cabaletta Bio Inc.’s risk profileQuarterly Earnings Report & Risk Controlled Daily Plans - newser.com
How supply chain issues affect Cabaletta Bio Inc. stock2025 Market Outlook & Safe Entry Momentum Stock Tips - newser.com
Is Cabaletta Bio Inc. stock a contrarian buyWeekly Gains Summary & Daily Stock Trend Watchlist - newser.com
Can Cabaletta Bio Inc. hit a new high this monthQuarterly Profit Report & Pattern Based Trade Signal System - newser.com
Will Cabaletta Bio Inc. see short term momentumOil Prices & Weekly Stock Performance Updates - newser.com
How Cabaletta Bio Inc. stock reacts to bond yieldsMarket Performance Recap & Smart Money Movement Alerts - newser.com
Visualizing Cabaletta Bio Inc. stock with heatmapsMarket Activity Summary & Capital Protection Trade Alerts - newser.com
Top Biotech Stocks To Follow TodayNovember 1st - MarketBeat
Cabaletta Bio’s Remarkable Surge: Positive Clinical Data and Elevated Price Targets - StocksToTrade
Cabaletta Bio Stock Price Rises After Positive Clinical Data Announcement - timothysykes.com
Cabaletta Bio, Inc. (NASDAQ:CABA) Short Interest Update - MarketBeat
Jennison Associates LLC Boosts Holdings in Cabaletta Bio, Inc. $CABA - MarketBeat
Why Does Cantor Fitzgerald See Over 1,000% Potential Upside For Cabaletta Bio Stock? - MSN
Can Cabaletta Bio Inc. stock maintain operating marginsEarnings Growth Summary & Safe Entry Trade Signal Reports - newser.com
Why Cabaletta Bio Inc. stock could rally in 2025Trade Entry Report & Verified Swing Trading Watchlist - newser.com
Cabaletta Bio Stock Climbs Amid Positive Clinical Developments - StocksToTrade
Cabaletta Bio Poised for Growth Amid Positive Clinical Data Releases - timothysykes.com
Cabaletta Bio (NASDAQ:CABA) Price Target Raised to $30.00 - MarketBeat
Advanced analytics toolkit walkthrough for Cabaletta Bio Inc.Weekly Trade Summary & Stepwise Entry and Exit Trade Signals - newser.com
CABA Stock: Cantor Fitzgerald Raises Price Target to $30, Mainta - GuruFocus
Comparing Cabaletta Bio Inc. in custom built stock radars2025 Market Trends & Scalable Portfolio Growth Methods - newser.com
Cabaletta Bio Reports Positive Rese-cel Data Across Myositis, SSc, and SLE Trials - Insider Monkey
Is Cabaletta Bio Inc. stock attractive for long term wealth buildingEarnings Miss & Consistent Profit Trading Strategies - newser.com
Is Cabaletta Bio Inc. stock attractive for ETFsJuly 2025 Update & Safe Entry Point Alerts - newser.com
Applying sector rotation models to Cabaletta Bio Inc.July 2025 Price Swings & Verified Momentum Stock Alerts - newser.com
10 Best Stocks Under $3 to Invest In - Insider Monkey
Cabaletta Bio Updates on CD19-CAR T Therapy Progress - TipRanks
Cabaletta Bio, Inc. Updates on Rese-cel Clinical Trials and FDA Alignment - TradingView
How Cabaletta Bio Inc. stock benefits from strong dollarPortfolio Gains Summary & Reliable Trade Execution Plans - fcp.pa.gov.br
Cabaletta’s CAR T Therapy Spurs Remissions in Small Lupus Trial - BioSpace
Cabaletta Bio stock maintains Buy rating at H.C. Wainwright on positive trial data - Investing.com Philippines
How Cabaletta Bio Inc. stock compares to growth peers2025 Technical Patterns & AI Powered Market Entry Strategies - fcp.pa.gov.br
Finanzdaten der Cabaletta Bio Inc-Aktie (CABA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):